glp-1/fgf21 agonist boehringer Alimentary Pharmacology & Therapeutics | Pharmacology Journal MASH field still hot as
Description
95% CI 0.04, 0.02), and GLP-1 RAs/SGLT2is (WMD: 0.03
Industry observers have noted that these drugs may prove "perpetually novel" through successive re-patenting for different uses, potentially maintaining monopoly positions even as earlier claims expire [40]
doi: 10.1016/j.cmet.2022.08.003
Corporate website
Safety Considerations and NHS Guidance on Berberine Whilst berberine appears generally well-tolerated in short-term studies (often using doses of 500 mg two to three times daily), several important safety considerations warrant attention
How do they affect gut health
